Here's a classic biotech story: a company's stock takes a nosedive because something unexpected happened in a clinical trial. In this case, it's Aardvark Therapeutics Inc. (AARD), and the "something" is a big, voluntary pause.
The company announced it's hitting the stop button on its Phase 3 HERO trial, which is testing a drug called ARD-101 for a condition called Prader-Willi Syndrome. When you see "voluntary pause" in a press release, you can usually translate that to "we saw something in the data that made us stop and think really hard before proceeding." And that's exactly what happened. The company is now doing a deep dive into safety data.
The immediate result? The stock was down a whopping 55.88% to $5.51 in premarket trading Monday, putting it uncomfortably close to its 52-week low of $4.88. They also won't be announcing the top-line results from this trial in the third quarter of 2026 as they had previously hoped. The timeline is officially up in the air.
What Exactly Did They See?
So, what spooked them? During routine safety checks in a separate study with healthy volunteers, researchers observed "reversible cardiac observations" at doses higher than the target therapeutic level. In simpler terms, at higher doses, some people showed heart-related side effects that went away. But seeing anything cardiac-related is a major red flag that demands immediate attention.
Tien Lee, Aardvark's CEO, framed the pause as a commitment to patient safety, saying the company needs to fully evaluate these signals. They plan to keep talking with the FDA and patient advocacy groups while figuring out the next move. It's the responsible thing to do, but it creates a lot of uncertainty for investors who were banking on a smooth path to data.
What Are the Analysts Saying?
Unsurprisingly, Wall Street is scrambling to reassess the situation. An analyst from William Blair put it bluntly: "At this point, it is admittedly difficult to properly assess prospects of ARD-101 in Prader-Willi syndrome given the limited available information." That's analyst-speak for "we have no idea what this means for the drug's future."
Andy T. Hsieh, another analyst, dug into the practical implications. He noted that this "severe disruption" might mean the current Phase 3 trial never gets finished as originally designed. But, he pointed out a potential silver lining: the company could choose to "unblind" the study early. Management had said that more than half of the 90-patient target was enrolled by mid-January. Unblinding that data could give everyone a decent-sized sample to judge whether the drug's benefits outweigh its risks.
"Assuming resolution of the cardiac safety event, Aardvark may be able to accelerate and streamline the second pivotal study with increased confidence in its statistical and powering assumptions," Hsieh added. So, if they can solve the safety puzzle, the path forward might actually become clearer and faster. That's a big "if," though.
The overall analyst consensus still shows a Buy rating with an average price target of $29.78, but that number is looking increasingly stale. The real story is in the recent flurry of downgrades:
- RBC Capital: Downgraded to Sector Perform (Lowers Target to $6.00)
- Stifel: Downgraded to Hold (Lowers Target to $6.00)
- Morgan Stanley: Downgraded to Equal-Weight (Lowers Target to $7)
- HC Wainwright: Downgrades to Neutral
All of those moves happened on March 2, right after the news broke. When you see multiple firms cutting their targets to the $6-$7 range from nearly $30, it tells you the perceived risk has gone way up, and the expected timeline for value has been pushed way out.
For now, Aardvark is in a holding pattern. The stock reaction reflects the fear that the pause could become a permanent roadblock, or at least a very long and expensive detour. The next steps—figuring out the cause of the safety signal and whether the current trial data is still usable—will determine if this is a temporary setback or a fundamental problem for ARD-101.
